Dynamic Technology Lab Private Ltd Makes New Investment in DaVita Inc. $DVA

Key Points

• Dynamic Technology Lab Private Ltd acquired a new stake in DaVita Inc. during Q1, purchasing 2,379 shares valued at approximately $364,000.
• DaVita reported strong earnings, with EPS of $2.95 for the last quarter, beating estimates, and revenue growth of 6.1% year-over-year.
• Institutional investors and hedge funds possess 90.12% of DaVita's stock, indicating significant institutional interest in the company.

Dynamic Technology Lab Private Ltd bought a new position in DaVita Inc. (NYSE:DVA - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 2,379 shares of the company's stock, valued at approximately $364,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in DVA. Wealth Enhancement Advisory Services LLC raised its stake in shares of DaVita by 2.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 3,551 shares of the company's stock valued at $531,000 after buying an additional 69 shares during the last quarter. UMB Bank n.a. boosted its holdings in DaVita by 65.5% in the 1st quarter. UMB Bank n.a. now owns 192 shares of the company's stock worth $29,000 after buying an additional 76 shares during the last quarter. Exchange Traded Concepts LLC boosted its holdings in DaVita by 8.9% in the 1st quarter. Exchange Traded Concepts LLC now owns 970 shares of the company's stock worth $148,000 after buying an additional 79 shares during the last quarter. Mather Group LLC. boosted its holdings in shares of DaVita by 7.0% during the 1st quarter. Mather Group LLC. now owns 1,201 shares of the company's stock worth $184,000 after purchasing an additional 79 shares during the last quarter. Finally, National Pension Service boosted its holdings in shares of DaVita by 74.3% during the 1st quarter. National Pension Service now owns 197 shares of the company's stock worth $30,000 after purchasing an additional 84 shares during the last quarter. Hedge funds and other institutional investors own 90.12% of the company's stock.

Insider Buying and Selling at DaVita

In related news, insider James O. Hearty sold 2,351 shares of DaVita stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total transaction of $352,650.00. Following the transaction, the insider owned 26,038 shares in the company, valued at approximately $3,905,700. The trade was a 8.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 1.50% of the company's stock.

DaVita Trading Down 0.6%

Shares of DVA traded down $0.79 during mid-day trading on Wednesday, reaching $129.32. The company had a trading volume of 81,889 shares, compared to its average volume of 842,989. The stock has a market cap of $9.25 billion, a price-to-earnings ratio of 12.71, a price-to-earnings-growth ratio of 0.94 and a beta of 1.13. The firm has a fifty day simple moving average of $137.94 and a 200-day simple moving average of $141.27. DaVita Inc. has a fifty-two week low of $126.07 and a fifty-two week high of $179.60. The company has a current ratio of 1.39, a quick ratio of 1.34 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share for the quarter, beating the consensus estimate of $2.70 by $0.25. The business had revenue of $3.38 billion for the quarter, compared to analyst estimates of $3.36 billion. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The business's quarterly revenue was up 6.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.00 EPS. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. On average, sell-side analysts anticipate that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

DVA has been the topic of a number of recent analyst reports. Barclays decreased their price objective on DaVita from $169.00 to $160.00 and set an "equal weight" rating on the stock in a report on Thursday, August 7th. Wall Street Zen upgraded shares of DaVita from a "hold" rating to a "buy" rating in a research note on Saturday. Bank of America decreased their target price on shares of DaVita from $145.00 to $140.00 and set an "underperform" rating for the company in a research note on Wednesday, September 10th. Finally, Truist Financial set a $148.00 price target on shares of DaVita in a report on Friday, August 8th. Three research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Reduce" and an average target price of $158.00.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.